Image

    Upadacitinib in the Treatment of a Patient with Atopic Dermatitis, Vitiligo, and Alopecia Areata: A Case Report and Literature Review

    June 2026 in “ Frontiers in Immunology ”
    T T Wang, Xiaofang Zhang, Yì Wáng … T T Wang
    Studysummary In this case report, a 57-year-old man with severe atopic dermatitis, vitiligo, and alopecia areata showed rapid and significant improvement after treatment with the JAK1 inhibitor upadacitinib, suggesting its potential as an effective monotherapy for these co-existing conditions when conventional therapies fail.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Janus Kinase Inhibitors for Alopecia Areata: A Review of Clinical Data Frontiers in Immunology · 2025
    2. Characteristics And Predictive Values Of Super-Responders In Alopecia Areata Under Tofacitinib Treatment: A Single-Center Retrospective Study Clinical and Experimental Dermatology · 2025
    3. Upadacitinib for Alopecia: Current Evidence and Clinical Insights Skin Appendage Disorders · 2025
    4. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    5. Janus Kinase (JAK) Inhibitors for the Treatment of Skin and Hair Disorders: A Review of Literature Journal of Dermatological Treatment · 2016
    6. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014